Subscribe to LexTalk to stay on top of today’s legal issue and trends.
Catapult Your Career |
Industry Insights & Trends |
Product Training & Tips
The below article is an excerpt courtesy State Net® Capitol Journal, written by Rich Ehisen.
The ACA created an “abbreviated licensure pathway” for biologic biosimilar medications becoming available on the drug market. States have since been considering bills that address that eventuality. In January, the FDA approved the first such biosimilar. But while the idea is that biosimilars will be used much like generic molecular drugs to drive down the cost of those medications, biosimilars are very different and present different regulatory issues for lawmakers.
In fact, according to a recent State Net Capitol Journal article, Nearly Half of States Considering 'Biologics' Bills, 22 states have filed or introduced bills or resolutions this session related to “biologics” or “biosimilars,” medical drugs generally derived from living cells. Three of the bills have been signed into law – Utah Utah’s HB 279, Virginia’s HB 1750 and Wyoming’s SB 3 – and a non-binding resolution – GEORGIA’s HR 34 – has been adopted. And bills have been sent to the governor in Colorado and Georgia.
While biosimilar medication is here, what it means for patients, insurers, doctors, pharmacists, drug manufacturers and state lawmakers is still far from determined.
If you would like to receive more information similar to the above, sign up for the StateNet Capitol Journal Newsletter.
The above article and image are courtesy of StateNet Capitol Journal.